NCT01790659View on ClinicalTrials.gov

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

PHASE3CompletedINTERVENTIONAL

Enrollment

399

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Cutaneous Leishmaniasis

Interventions

DRUG

WR 279,396

WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%

DRUG

Paromomycin

Paromomycin alone

Trial Locations (1)

Unknown

Instituto Conmemorativo Gorgas de Estudios de la Salud,, Panama City

All Listed Sponsors

lead

U.S. Army Medical Research and Development Command

FED

NCT01790659 - Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama | Biotech Hunter | Biotech Hunter